Pancreatic Carcinoma Non-resectable Clinical Trial
Official title:
Phase I Time-to-Event Continual Reassessment (TITE-CRM) Dose Escalation Trial of CyberKnife® Stereotactic Body Radiotherapy (SBRT) Boost With Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Pancreatic Cancer
Currently the standard treatment for locally advanced, unresectable pancreatic cancer
consists either of chemotherapy by itself or a combination of chemotherapy plus radiation
therapy or no treatment at all. Unfortunately, no treatment thus far has been able to provide
patients with a consistent chance for a cure although there are rare patients who will live
for many years after treatment. For most patients the chemotherapy or chemotherapy plus
radiation will maintain or improve quality of life by keeping the cancer under control for a
period of time.
Approximately 25-30% of patients with early pancreatic cancer who are able to have the cancer
completely removed surgically will live beyond 5 years and will be considered cured. This
tells us that aggressive treatment directed at the tumour in the pancreas can lead to cure.
For the majority of patients who can not have an operation, giving more radiation as part of
the treatment may be a strategy that results in better control of the tumour in the pancreas
which may or may not result in patients living longer.
The purpose of this study is to test the safety of adding a higher dose (a "boost" dose) of
radiation using a radiation unit called CyberKnife when combined with standard chemotherapy
and radiation for patients with locally advanced, unresectable pancreatic cancer.
Participants on this study will receive a 'boost' dose of radiation which consists of 3
treatments over 1 week. The participants will then receive the standard of care treatment of
chemotherapy and standard radiation therapy over a 5 week period, which will be followed by
the conventional 20 weeks of chemotherapy alone. The participants will then be followed for
progression of disease and toxicity related to the boost treatment for up to 5 years.
Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision not previously possible using older equipment. The CyberKnife® Robotic Radiosurgery System (Accuray, Sunnyvale California, USA) is a radiation unit specifically designed to focus beams of radiation accurately anywhere in the body. It is able to track, detect and correct for any tumor movement during treatment by using a sophisticated image guidance system. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01593475 -
Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT00761345 -
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Terminated |
NCT01836432 -
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
|
Phase 3 | |
| Terminated |
NCT01851174 -
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT02405585 -
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
|
Phase 2 |